Mikhail Blagosklonny: Forging the Future of Innovative Cancer Cure & Anti-Aging

Oncotarget has become well-established in the medical Industry and utilized by countless physicians worldwide for attaining relevant remedial research data as it pertains to the biomedical field. Oncotarget publishes multi-faceted scientific studies so that medical communities can quickly access the most up-to-date evidence and findings. Oncotarget bridges the gap that sometimes occurs between the varied medical areas regarding shared information and data collection. Mikhail Blogosklonny is one of the leading chief operators of Oncotarget and is an expert in cancer, anti-aging and biomedical science. His scientific work has led to the breakthrough of an anti-aging and cancer treatment drug, Rapamycin.

Rapamycin acts an immunosuppressant and is considered by many to be very effective when the administration of it is via pulse dosing. Oncotarget has been so popular they have expanded their peer-review research paper areas to Autophagy and Cell Death, Immunology and Microbiology, Chromosome Function and Gerotarget Aging.Dr. Blagosklonny is a medical instructor at Roswell Park Cancer Institute as an Oncologist. He is originally descended from Russia where he attained his Ph.D in Experimental Medicine and Internal Medicines at First Pavlov State Medical University in St. Petersburg. After coming to the United States, he worked as an Oncologist Professor at the Roswell Park Cancer Institute in Buffalo, New York. He also served as professor at New York Medical college in Valhalla. Dr. Mikhail Blagosklonny has a vast acumen in bio-metrics and specializes in the areas below.

  • Drug resistance to cellular function
  • Mitosis
  • Apoptosis
  • Signal Transduction
  • Discovering innovative ways to remedy cancer and prevent anti-aging
  • Free Radical and Oxidative Processes
  • Hyper Function Theory and Application

Mikhail has two other journals he operates that are similar to Oncotarget. They are Oncoscience and Aging and Cell Cycle. He is a regular contributor to many other publications and include the American Journal of Pathology, the International journal of Medicine and Plos One. Blagosklonny serves on the Board of Cell Death and Differentiation. He discovered that a unique framework should be orchestrated as a platform and applied when considering what causes anti-aging and his approach draws a fine between old data and points to the integration of hyper function and hypertrophy. This is in opposition to previous scientific belief that aging was caused by untargeted molecular damage. Mikhail has been a major contributor in the discovery of a cancer cure and continues to act a pioneer in the advancement of a sick free world.

scmadmin